<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231422</url>
  </required_header>
  <id_info>
    <org_study_id>BRAND-003</org_study_id>
    <nct_id>NCT04231422</nct_id>
  </id_info>
  <brief_title>A Proof of Concept Top Evaluate a Novel Penile Lengthening Protocol</brief_title>
  <official_title>A Proof of Concept Top Evaluate a Novel Penile Lengthening Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Judson Brandeis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BrandeisMD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to examine and quantify the efficacy and safety of a new
      treatment protocol using platelet-rich plasma for penile length enhancement.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2019</start_date>
  <completion_date type="Anticipated">July 12, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 12, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stretched penile length</measure>
    <time_frame>baseline to six months</time_frame>
    <description>Change in length of stretched, flaccid penile length</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SHIM Score</measure>
    <time_frame>baseline to six months</time_frame>
    <description>Change in erectile function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDD-YBOCS</measure>
    <time_frame>baseline to six months</time_frame>
    <description>Change in body dysmorphia scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Measurement</measure>
    <time_frame>baseline to six months</time_frame>
    <description>Incidence of adverse events and serious adverse events</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Penile Elongation</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <description>Monthly intracavernosal platelet-rich plasma injection + daily physical manipulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Platelet-rich plasma</intervention_name>
    <description>12mL of platelet-rich plasma injected into cavernosal bodies bilaterally</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study participants comprised of men with a desire for penile elongation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Stretched penile length between 3.5 - 8.0 in

          2. Age 20-55 years of age

          3. Desire penile length elongation

          4. Willing to complete all aspects of combined treatment plan

          5. Able to measure erect penile length and mid-shaft girth at 1-month intervals

          6. Judged to be in good health based on medical history, physical exam, and laboratory
             profile

          7. Is willing and able to cooperate with the requirement of the study (e.g. completion of
             all planned study visits)

        Exclusion Criteria:

          1. No prior surgical Peyronie's disease treatment

          2. No chordee with or without hypospadias

          3. No infiltration by benign or malignant mass

          4. No active STD

          5. No infiltration by an infectious agent such as lymphogranuloma venereum

          6. No uncontrolled psychiatric conditions

          7. No uncontrolled neurologic conditions

          8. No other uncontrolled medical conditions such as HTN or DM

          9. No history of spontaneous priapism

         10. Is unable to safely use the study devices as determined by the principal investigator

         11. No thrombosis of the dorsal penile artery or vein

         12. No known history of coagulation disorder

         13. No known history of stroke, bleeding, or another significant medical conditional which
             the investigator deems makes the subject unsuitable for enrollment in the study

         14. Testosterone level lower than 500
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judson Brandeis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BrandeisMD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judson Brandeis, MD</last_name>
    <phone>510-587-3000</phone>
    <email>Judson@BrandeisMD.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>BrandeisMD</name>
      <address>
        <city>San Ramon</city>
        <state>California</state>
        <zip>94583</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judson Brandeis, MD</last_name>
      <phone>510-587-3000</phone>
      <email>Judson@BrandeisMD.com</email>
    </contact>
    <investigator>
      <last_name>Scott Lu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>BrandeisMD</investigator_affiliation>
    <investigator_full_name>Judson Brandeis</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>platelet-rich plasma</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

